Gladys

Gladys Therapeutics is a French biotechnology company focused on developing next-generation immunotherapies for the treatment of cancer. Founded by David Sourdive, a co-founder of Cellectis, the company leverages advanced synthetic biology and cell engineering to create therapies designed to overcome the immunosuppressive environment of tumors. Gladys aims to provide more effective and precise treatment options for patients with hard-to-treat malignancies by engineering immune cells with enhanced capabilities. The company is currently in the pre-clinical stage, focusing on building its proprietary technology platform and early-stage pipeline. Headquartered in Paris, Gladys Therapeutics represents a new wave of precision oncology startups emerging from the European biotech ecosystem.